ESR1 and breast cancer: In general, ER+ PRSRLR and ER+ PRSLRR showed similar performance to the corresponding primary PRSs of ER+ breast cancer, whereas the performance of the ER+ PRSANN of ER+ breast cancer was worse than that of the primary PRSANN (IQ-OR 1.60 vs. 1.96; AUC 0.612 vs. 0.620; O/E OR 1.16 vs. 1.09).